In oligonucleotide therapeutics as in the property market, three things matter – location, location, location. If there are twisting roads with lots of compulsory diversions between
Transcriptional activation by saRNAs – a mechanism distinct from RNAi? In 2006 Long-Cheng Li et al.1 first
Are long noncoding RNAs the new frontier in cancer treatment? Long noncoding RNAs (lncRNAs) have been defined as non-coding transcripts of >200 nucleotides in length to distinguish them from miRNAs. They make up >75% of the actively transcribed genome and over 85%
With CRISPR/Cas in the picture how does antisense oligonucleotide-mediated splice modulation fit in?
With CRISPR/Cas in the picture how does antisense oligonucleotide-mediated splice modulation fit in? The rapid development and adaptation of CRISPR/Cas9 nucleases which can be engineered to target and edit nearly any DNA sequence